Energy supplements protect pancreas from side effects of AsparaginaseDr Julia Gerasimenko, Cardiff University
Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcomaProfessor Sibylle Mittnacht, UCL Cancer Institute
Exploring the role of a novel tumour suppressor in leukaemiaDr David Clynes, The MRC Weatherall Institute of Molecular Medicine
Preservation and analysis of pathology records and family histories of children with cancerDr John Bithell, University of Oxford
Markers of hypothalamic dysfunction in children with hypothalamo-pituitary tumours or pituitary maldevelopmentDr Manuela Cerbone, University College London
Modification of the Asparaginase-based drugs for ALLDr Oleg Gerasimenko, Cardiff University
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.